Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide
Go back to Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide| (NYSE: ARCH) | Delayed: 134.83 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $134.83 | 52 Week High | $86.47 | |||
| Open | $134.83 | 52 Week Low | $59.05 | |||
| Day High | $134.83 | P/E | N/A | |||
| Day Low | $134.83 | EPS | $0.00 | |||
| Volume | 408 | |||||
